ARWR
Price
$13.47
Change
-$0.05 (-0.37%)
Updated
Apr 29, 04:59 PM (EDT)
Capitalization
1.86B
9 days until earnings call
RARE
Price
$38.05
Change
+$0.07 (+0.18%)
Updated
Apr 29, 04:59 PM (EDT)
Capitalization
3.57B
2 days until earnings call
Ad is loading...

ARWR vs RARE

Header iconARWR vs RARE Comparison
Open Charts ARWR vs RAREBanner chart's image
Arrowhead Pharmaceuticals
Price$13.47
Change-$0.05 (-0.37%)
Volume$14.35K
Capitalization1.86B
Ultragenyx Pharmaceutical
Price$38.05
Change+$0.07 (+0.18%)
Volume$19.76K
Capitalization3.57B
ARWR vs RARE Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. RARE commentary
Apr 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and RARE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 30, 2025
Stock price -- (ARWR: $13.52 vs. RARE: $37.98)
Brand notoriety: ARWR: Notable vs. RARE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 57% vs. RARE: 63%
Market capitalization -- ARWR: $1.86B vs. RARE: $3.57B
ARWR [@Biotechnology] is valued at $1.86B. RARE’s [@Biotechnology] market capitalization is $3.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ARWR and RARE are a good buy in the short-term.

Price Growth

ARWR (@Biotechnology) experienced а +11.92% price change this week, while RARE (@Biotechnology) price change was +7.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.09%. For the same industry, the average monthly price growth was -2.03%, and the average quarterly price growth was -10.94%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.57B) has a higher market cap than ARWR($1.86B). RARE YTD gains are higher at: -9.722 vs. ARWR (-28.085). RARE has higher annual earnings (EBITDA): -469M vs. ARWR (-580.69M). RARE has more cash in the bank: 610M vs. ARWR (553M). RARE has less debt than ARWR: RARE (40.3M) vs ARWR (525M). RARE has higher revenues than ARWR: RARE (560M) vs ARWR (2.5M).
ARWRRAREARWR / RARE
Capitalization1.86B3.57B52%
EBITDA-580.69M-469M124%
Gain YTD-28.085-9.722289%
P/E RatioN/AN/A-
Revenue2.5M560M0%
Total Cash553M610M91%
Total Debt525M40.3M1,303%
FUNDAMENTALS RATINGS
ARWR vs RARE: Fundamental Ratings
ARWR
RARE
OUTLOOK RATING
1..100
1120
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8662
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (73) in the Biotechnology industry is in the same range as ARWR (96). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

RARE's SMR Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

RARE's Price Growth Rating (62) in the Biotechnology industry is in the same range as ARWR (86). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for RARE (100). This means that ARWR’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRRARE
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 13 days ago
83%
Bearish Trend 22 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X94978.7500001223.914100
+1.31%
Bitcoin cryptocurrency
GME27.590.13
+0.47%
GameStop Corp
AAPL210.140.86
+0.41%
Apple
TSLA285.880.93
+0.33%
Tesla
SPY550.850.21
+0.04%
SPDR® S&P 500® ETF

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+2.04%
DNLI - ARWR
58%
Loosely correlated
+3.64%
NTLA - ARWR
56%
Loosely correlated
+2.05%
BEAM - ARWR
55%
Loosely correlated
+1.43%
RGNX - ARWR
54%
Loosely correlated
-0.22%
ETNB - ARWR
53%
Loosely correlated
+6.63%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with ARWR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-0.29%
ARWR - RARE
48%
Loosely correlated
+2.04%
CRNX - RARE
47%
Loosely correlated
+2.22%
DNLI - RARE
47%
Loosely correlated
+3.64%
IONS - RARE
47%
Loosely correlated
+0.13%
RVMD - RARE
46%
Loosely correlated
+6.96%
More